TauRx Therapeutics Selects BioClinica, Inc. for eClinical and Imaging Solutions
11/5/2012 10:04:01 AM
NEWTOWN, Pa.--(BUSINESS WIRE)--BioClinica®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that TauRx Therapeutics has signed agreements with BioClinica to use Trident IWR/IVR and Imaging Core Lab (ICL) solutions to support its upcoming Phase III clinical trials. TauRx, a Singapore-based company, focuses its research on therapies and diagnostics for the treatment of Alzheimer's disease and other neurodegenerative disorders. With primary research facilities in Aberdeen in the United Kingdom, TauRx is the latest European customer to select BioClinica for both Imaging and eClinical offerings.